trending Market Intelligence /marketintelligence/en/news-insights/trending/5ixav7gsxnvx8viythzeoq2 content esgSubNav
In This List

Evolent Health issues Q1, FY'18 outlook

Blog

Fintech Intelligence Digital Newsletter: May 2021

Street Talk – Episode 76: Record pace of fintech M&A, funding in Q1'21 has legs

Fintech Intelligence Digital Newsletter: April 2021

Podcast

Street Talk | Episode 76: Record pace of fintech M&A, funding in Q1'21 has legs


Evolent Health issues Q1, FY'18 outlook

Evolent Health issued outlook for full year 2018 and the first quarter.

For full year 2018, the company expects adjusted revenue of approximately $565.0 million to $585.0 million, and adjusted EBITDA of about $18.0 million to $23.0 million. Adjusted services revenue is expected to be between about $495.0 million and $510.0 million, true health premium revenue is estimated to be about $90.0 million to $95.0 million, and intercompany eliminations are expected to be nearly $20.0 million.

For the first quarter, the company expects adjusted revenue of about $139.0 million to $143.0 million, and adjusted EBITDA of approximately $3.0 million to $5.0 million. Adjusted services revenue is expected to be approximately $122.0 million to $124.0 million, true health premium revenue is expected to be approximately $22.0 million to $24.0 million, and intercompany eliminations are estimated to be roughly $5.0 million for the quarter.

For the fourth quarter of 2017, Evolent Health reported a net loss attributable to the company of $13.2 million, or 18 cents per share, compared to a net loss of $17.4 million, or 33 cents per share, in the year-ago period.

The S&P Capital IQ consensus GAAP EPS estimate for the fourth quarter of 2017 was a loss of 17 cents.

For full year 2017, the company posted a net loss attributable to the company of $60.7 million, or 94 cents per share, compared to a net loss of $159.7 million, or $3.55 per share, in 2016.

The S&P Capital IQ consensus GAAP EPS estimate for 2017 was a loss of 92 cents.